Dr. Ari M. Melnick on Biomarkers in Lymphoma

Ari M. Melnick, MD
Published: Thursday, Apr 11, 2013

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, comments on biomarkers in lymphoma.

Studies of epigenetic regulation in lymphomas are identifying clinically-useful biomarkers and revealing biological insights into how lymphomas function. Lymphomas exhibit a great degree of epigenetic heterogeneity, which is an indicator of disease aggressiveness and increases the populations of cells that can survive chemotherapy and repopulate the disease.

Cytosine methylation patterns in lymphoma are reversible. The potential remains to inhibit DNA methyltransferases and overcome the negative effects of epigenetic heterogeneity.

SELECTED
LANGUAGE
Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, comments on biomarkers in lymphoma.

Studies of epigenetic regulation in lymphomas are identifying clinically-useful biomarkers and revealing biological insights into how lymphomas function. Lymphomas exhibit a great degree of epigenetic heterogeneity, which is an indicator of disease aggressiveness and increases the populations of cells that can survive chemotherapy and repopulate the disease.

Cytosine methylation patterns in lymphoma are reversible. The potential remains to inhibit DNA methyltransferases and overcome the negative effects of epigenetic heterogeneity.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesNov 29, 20192.0
Advances in™ ALL: The Role of T-Cell Engaging Immunotherapy in Treating Relapsed DiseaseNov 30, 20191.0
Publication Bottom Border
Border Publication
x